Computational approaches to therapeutic antibody design: established methods and emerging trends

Richard A. Norman(Friedreich's Ataxia Research Alliance), Francesco Ambrosetti(Utrecht University), Alexandre M. J. J. Bonvin(Utrecht University), Lucy J. Colwell(University of Cambridge), Sebastian Kelm(UCB Pharma (United Kingdom)), Sandeep Kumar(Boehringer Ingelheim (United States)), Konrad Krawczyk
Briefings in Bioinformatics
July 11, 2019
Cited by 233Open Access
Full Text

Abstract

Antibodies are proteins that recognize the molecular surfaces of potentially noxious molecules to mount an adaptive immune response or, in the case of autoimmune diseases, molecules that are part of healthy cells and tissues. Due to their binding versatility, antibodies are currently the largest class of biotherapeutics, with five monoclonal antibodies ranked in the top 10 blockbuster drugs. Computational advances in protein modelling and design can have a tangible impact on antibody-based therapeutic development. Antibody-specific computational protocols currently benefit from an increasing volume of data provided by next generation sequencing and application to related drug modalities based on traditional antibodies, such as nanobodies. Here we present a structured overview of available databases, methods and emerging trends in computational antibody analysis and contextualize them towards the engineering of candidate antibody therapeutics.


Related Papers

No related papers found

Powered by citation graph analysis